Development of new immunotherapies using melanoma antigens recognized by T cells

Yutaka Kawakami

Research output: Contribution to journalArticle

Abstract

Melanoma is a relatively immunogenic cancer and a good model to evaluate the possibilities of immunotherapies. Recent progress of molecular biology and immunology has allowed us to understand immune responses to human cancer at the molecular level. Although antigens for CD4+ T cells have not well been identified, various melanoma antigens recognized by CD8+ T cells have been identified, including tissue specific proteins (melanosomal proteins), proteins expressed in testis and a variety of cancers (Cancer-Testis antigens) and tumor specific mutated proteins. The immunological features of these antigens have been characterized for development of new immunotherapies. Based on these findings, antigen specific immunotherapies have been developed. Some of the phase I clinical trials with the identified melanoma antigens demonstrated anti-tumor effects. Immunization with the modified gp100 epitope that had high MHC binding affinity, in conjunction with incomplete freund adjuvant and high-dose IL-2, resulted in a 42 % response rate (CR+PR). Immunization with dendritic cells pulsed with tumor lysates or epitope peptides resulted in a 31 % response rate in metastatic melanoma. These immunotherapies need to be improved through modifications and better understanding of tumor escape mechanisms.

Original languageEnglish
Pages (from-to)1187-1194
Number of pages8
JournalBiotherapy
Volume12
Issue number9
Publication statusPublished - 1998
Externally publishedYes

Fingerprint

Melanoma-Specific Antigens
Immunotherapy
T-Lymphocytes
Neoplasms
Epitopes
Melanoma
Immunization
Proteins
Tumor Escape
Antigens
CD4 Antigens
Clinical Trials, Phase I
Testicular Neoplasms
Neoplasm Antigens
Allergy and Immunology
Dendritic Cells
Interleukin-2
Testis
Molecular Biology
Peptides

Keywords

  • Autoimmunity
  • Dendritic cells
  • Immunotherapy
  • Melanoma antigens
  • T-lymphocytes

ASJC Scopus subject areas

  • Cancer Research
  • Immunology and Allergy

Cite this

Development of new immunotherapies using melanoma antigens recognized by T cells. / Kawakami, Yutaka.

In: Biotherapy, Vol. 12, No. 9, 1998, p. 1187-1194.

Research output: Contribution to journalArticle

Kawakami, Yutaka. / Development of new immunotherapies using melanoma antigens recognized by T cells. In: Biotherapy. 1998 ; Vol. 12, No. 9. pp. 1187-1194.
@article{e91c576f92f94c76a2d8f1e72b9f0763,
title = "Development of new immunotherapies using melanoma antigens recognized by T cells",
abstract = "Melanoma is a relatively immunogenic cancer and a good model to evaluate the possibilities of immunotherapies. Recent progress of molecular biology and immunology has allowed us to understand immune responses to human cancer at the molecular level. Although antigens for CD4+ T cells have not well been identified, various melanoma antigens recognized by CD8+ T cells have been identified, including tissue specific proteins (melanosomal proteins), proteins expressed in testis and a variety of cancers (Cancer-Testis antigens) and tumor specific mutated proteins. The immunological features of these antigens have been characterized for development of new immunotherapies. Based on these findings, antigen specific immunotherapies have been developed. Some of the phase I clinical trials with the identified melanoma antigens demonstrated anti-tumor effects. Immunization with the modified gp100 epitope that had high MHC binding affinity, in conjunction with incomplete freund adjuvant and high-dose IL-2, resulted in a 42 {\%} response rate (CR+PR). Immunization with dendritic cells pulsed with tumor lysates or epitope peptides resulted in a 31 {\%} response rate in metastatic melanoma. These immunotherapies need to be improved through modifications and better understanding of tumor escape mechanisms.",
keywords = "Autoimmunity, Dendritic cells, Immunotherapy, Melanoma antigens, T-lymphocytes",
author = "Yutaka Kawakami",
year = "1998",
language = "English",
volume = "12",
pages = "1187--1194",
journal = "Biotherapy",
issn = "0914-2223",
publisher = "Japanese Society for Cancer Chemotherapy",
number = "9",

}

TY - JOUR

T1 - Development of new immunotherapies using melanoma antigens recognized by T cells

AU - Kawakami, Yutaka

PY - 1998

Y1 - 1998

N2 - Melanoma is a relatively immunogenic cancer and a good model to evaluate the possibilities of immunotherapies. Recent progress of molecular biology and immunology has allowed us to understand immune responses to human cancer at the molecular level. Although antigens for CD4+ T cells have not well been identified, various melanoma antigens recognized by CD8+ T cells have been identified, including tissue specific proteins (melanosomal proteins), proteins expressed in testis and a variety of cancers (Cancer-Testis antigens) and tumor specific mutated proteins. The immunological features of these antigens have been characterized for development of new immunotherapies. Based on these findings, antigen specific immunotherapies have been developed. Some of the phase I clinical trials with the identified melanoma antigens demonstrated anti-tumor effects. Immunization with the modified gp100 epitope that had high MHC binding affinity, in conjunction with incomplete freund adjuvant and high-dose IL-2, resulted in a 42 % response rate (CR+PR). Immunization with dendritic cells pulsed with tumor lysates or epitope peptides resulted in a 31 % response rate in metastatic melanoma. These immunotherapies need to be improved through modifications and better understanding of tumor escape mechanisms.

AB - Melanoma is a relatively immunogenic cancer and a good model to evaluate the possibilities of immunotherapies. Recent progress of molecular biology and immunology has allowed us to understand immune responses to human cancer at the molecular level. Although antigens for CD4+ T cells have not well been identified, various melanoma antigens recognized by CD8+ T cells have been identified, including tissue specific proteins (melanosomal proteins), proteins expressed in testis and a variety of cancers (Cancer-Testis antigens) and tumor specific mutated proteins. The immunological features of these antigens have been characterized for development of new immunotherapies. Based on these findings, antigen specific immunotherapies have been developed. Some of the phase I clinical trials with the identified melanoma antigens demonstrated anti-tumor effects. Immunization with the modified gp100 epitope that had high MHC binding affinity, in conjunction with incomplete freund adjuvant and high-dose IL-2, resulted in a 42 % response rate (CR+PR). Immunization with dendritic cells pulsed with tumor lysates or epitope peptides resulted in a 31 % response rate in metastatic melanoma. These immunotherapies need to be improved through modifications and better understanding of tumor escape mechanisms.

KW - Autoimmunity

KW - Dendritic cells

KW - Immunotherapy

KW - Melanoma antigens

KW - T-lymphocytes

UR - http://www.scopus.com/inward/record.url?scp=0031789125&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031789125&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0031789125

VL - 12

SP - 1187

EP - 1194

JO - Biotherapy

JF - Biotherapy

SN - 0914-2223

IS - 9

ER -